CureusAug 19, 2024

Using Glucagon-Like Peptide-1 Drugs to Restore Gut Balance for Obesity and Metabolic Health

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Mar 28, 2026

Abstract

Obesity significantly impacts gut microbial composition, exacerbating metabolic dysfunction and weight gain.

Glucagon-like peptide-1 (GLP-1) agonists may promote beneficial bacterial populations while reducing harmful species.
These agents could enhance gut barrier integrity, potentially reducing permeability and systemic inflammation.
GLP-1 agonists may improve metabolic functions by increasing the production of short-chain fatty acids, which serve as energy sources for colon cells.
By increasing microbial diversity, GLP-1 agonists may help create a more resilient gut microbiome.
Shifting gut microbiota toward a healthier profile is associated with disrupting the cycle of obesity-induced gut dysbiosis and inflammation.

Simplified

Obesity significantly impacts gut microbial composition, exacerbating metabolic dysfunction and weight gain. Traditional treatment methods often fall short, underscoring the need for innovative approaches. Glucagon-like peptide-1 (GLP-1) agonists have emerged as promising agents in obesity management, demonstrating significant potential in modulating gut microbiota. These agents promote beneficial bacterial populations, such as,,, while reducing harmful species like. By influencing gut microbiota composition, GLP-1 agonists enhance gut barrier integrity, reducing permeability and systemic inflammation, which are hallmarks of metabolic dysfunction in obesity. Additionally, GLP-1 agonists improve metabolic functions by increasing the production of short-chain fatty acids like butyrate, propionate, and acetate, which serve as energy sources for colonocytes, modulate immune responses, and enhance the production of gut hormones that regulate appetite and glucose homeostasis. By increasing microbial diversity, GLP-1 agonists create a more resilient gut microbiome capable of resisting pathogenic invasions and maintaining metabolic balance. Thus, by shifting the gut microbiota toward a healthier profile, GLP-1 agonists help disrupt the vicious cycle of obesity-induced gut dysbiosis and inflammation. This review highlights the intricate relationship between obesity, gut microbiota, and GLP-1 agonists, providing valuable insights into their combined role in effective obesity treatment and metabolic health enhancement. Bacteroides Lactobacillus and Bifidobacterium Enterobacteriaceae

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

PubMed

Using Glucagon-Like Peptide-1 Drugs to Restore Gut Balance for Obesity and Metabolic Health

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief